Titch talks Biotech - Sydney October 2026

Titch talks Life Sciences — Sydney

Titch talks is bringing together some of the ASX's most promising life sciences companies for an intimate lunch briefing in the Sydney CBD.

Over lunch, the presenting companies will each take the floor for a focused 15-minute presentation, covering their pipeline, milestones and investment case — followed by open Q&A.

Details

📍 CBD venue — The Argyle Stores - with menu from The Cut
🗓️ Wednesday 21 October 2026
🕛 12:00pm – 2:30pm

Presenting companies:

Invion Limited (ASX: IVX) — Presented by Thian Chew, Chairman & CEO.

A clinical-stage life sciences company developing Photosoft, a next-generation photodynamic therapy (PDT) platform for cancer and infectious diseases. Lead candidate INV043 has completed a Phase II prostate cancer trial and is in an ongoing Phase I/II skin cancer trial.

Clever Culture Systems (ASX: CC5) — Presented by Brent Barnes, CEO.

An AI-driven med-tech company automating microbiology testing for pharmaceutical and clinical labs, with the only FDA-cleared AI platform for automated culture plate reading. Customers include AstraZeneca, Novo Nordisk and Bristol Myers Squibb.

Percheron Therapeutics (ASX: PER) — Presented by Michael Baker, PhD, MBA, CEO.

A clinical-stage biotechnology company developing targeted immunotherapies for difficult-to-treat haematological malignancies and solid tumours. The company’s sole clinical-stage candidate, HMBD-002, is a monoclonal antibody targeting V-domain Ig suppressor of T-cell activation (VISTA), an immune checkpoint regulator implicated in treatment resistance and poor prognosis.

Natural Medtech (Pre-IPO) — Presented by Luke McFarlane, CEO & Co-founder.

A Melbourne-based biosynthesis company manufacturing GMP-grade psilocybin and other psychedelic compounds for clinical and commercial use, aiming to lower the cost of global mental health treatment.

Places are limited and RSVP is essential. Hosted by Titch Communications.

Contact hannah@titchcomms.com.au for help